P53 deletion is independently associated with increased age and decreased survival in a cohort of Chinese patients with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2182-2185

  Jia, Zhuxia ^a   He, Jinyuan ^a   Cen, Ling ^a   Han, Wenmin ^a   Jiang, Naike ^a   Yang, Jianhe ^a   Zhou, Min ^a  

^a THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cytogenetics; Diffuse large B cell lymphoma; elderly; prognosis

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; MALE; ONCOGENE C MYC; PRIORITY JOURNAL;

AGE FACTORS; AGED; COHORT STUDIES; FEMALE; GENE DELETION; GENE REARRANGEMENT; GENES, BCL-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867164599     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.686106     Document Type: Article

References (14)

1. Shi YK. Lymphoma. 1st ed. Beijing: Peking University Medical Press; 2007. pp 129-151.
2. Harris NL, Jaf e ES, Stein HJ, et al. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Xue Y. The c ytogenetics and pictures of leukemia. Tianjing: Tianjing Science and Technology Publishing House; 2003. pp 7-12.
4. A Clinical Evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Te Non-Hodgkin's Lymphoma Classif cation Project. Blood 1997;89:3909-3918.
5. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inf ammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60. (Pubitemid 43057092)
6. Xiao C, Su ZL, Wu QL, et al. Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 2005;34:22-27.
7. Zhang YN, Zhouo XG, Zhang SH, et al. Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms. Zhonghua Bing Li Xue Za Zhi 2005;34:193-197.
8. Winter JN, Weller E, Horning SJ, et al. Prognostic signif cance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213. (Pubitemid 43801342)
9. Raetz EA, Perkins SL, Carlson MA, et al. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-myc expression in pediatric anaplastic large cell lymphomas. Am J Pathol 2002;161:875-883. (Pubitemid 34988375)
10. Leroy K, Haioun C, Lepage E, et al. P53 gene deletions are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002;13:1108-1115.
11. Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and P53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 2002;41:322-330. (Pubitemid 35279029)
12. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratif cation in diffuse large B-cell lymphoma. Blood 2002;99:1136-1143. (Pubitemid 34547064)
13. Jerkeman M, Aman P, Cavallin-Stahl E, et al. Prognostic inplications of BCL-6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Int J Oncol 2002;20:161-165.
14. Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the cutaneous variant. Br J Haematol 2004;127:173-183. (Pubitemid 39371810)